BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

nContact Surgical, Inc.: Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation


9/22/2010 8:30:41 AM

MORRISVILLE, N.C., Sept. 21 /PRNewswire/ -- During the recent Atrial Fibrillation Session of the Techno College at the European Association of Cardiac Thoracic Surgeons in Geneva, Switzerland, Professor Borut Gersak, Head of Cardiac Surgery from University Medical Center in Ljubljana, Slovenia challenged his audience of more than 1,000 medical professionals to think differently about existing atrial fibrillation surgical approaches. He called for the cardiac surgeons in attendance to encourage cardiologists to refer atrial fibrillation patients for stand-alone, interdisciplinary hybrid procedures that are significantly less invasive, yet allow for a more complete treatment of the condition and improved results.

Professor Gersak has been instrumental in developing the Convergent Procedure, a completely closed-chest surgical technique that is designed to treat all types of atrial fibrillation, the most common cardiac arrhythmia (abnormal heartbeat) affecting millions of people worldwide.

The Convergent Procedure is a combined epicardial-endocardial ablation approach. A cardiac surgeon initially creates a comprehensive bi-atrial lesion pattern through a 2.5cm abdominal incision, without chest incisions, ports, or lung deflation. The surgeon utilizes the nContact coagulation device during epicardial ablation to create continuous, linear lesions on a beating heart. Within the same setting, an electrophysiologist will then perform endocardial ablation to complete the lesion pattern and utilize mapping and diagnostics to ensure procedure endpoints are achieved.

"Cardiologists don't accept surgical ablation procedures as 'minimally invasive' if they require multiple thoracic incisions and lung deflation. As such, procedures for treating atrial fibrillation must eliminate invasive chest incisions while allowing surgeons to have direct visualization of the heart and their instruments through endoscopes," stated Professor Gersak. "This subthoracic total endoscopic 'subtle' approach to surgery is the key to adoption of the Convergent Procedure, which provides a complete interdisciplinary approach to address the tougher atrial fibrillation patient populations with improved procedure times, less patient discomfort, and quicker recovery."

At the Techno College Session, cardiac surgical leaders echoed the call for improved technologies that enable less invasive surgical approaches and precise diagnostic endpoints to predict results for atrial fibrillation procedures.

Professor Gerhard Wimmer Greinecker, Chief of Cardiac Surgery at the Heart and Vascular Center in Bad Bevensen, Germany, who chaired the atrial fibrillation session, joined Professor Gersak in support of "subtle surgery" for treating atrial fibrillation. "Techniques such as the Convergent Procedure are the future of atrial fibrillation treatment as it leaves the thoracic cavity and lungs undisturbed, while enabling the cardiac surgeon to have visibility and access to the heart. This will be an important advantage in the minds of cardiologists and patients, as the approach is thought of simply as a 'procedure' rather than surgery. Demand for 'subtle surgical approaches' will continue to drive future innovation and adoption within the atrial fibrillation market."

About nContact Surgical, Inc.

nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.

Media Contacts

nContact Surgical. Inc.

Edgar Rey

1001 Aviation Parkway, Ste 400

nContact Surgical

Morrisville, NC 27560 USA

T (404) 285-0466

T (919) 466-9810

erey@ncontactsurgical.com

F (919) 466-9811



Kimberly Muscara/Jason Rando

www.ncontactsurgical.com

The Ruth Group


T (646) 536-7011/7025


kmuscara@theruthgroup.com




SOURCE nContact Surgical, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->